Bausch + Lomb (BLCO)

• Market cap: $5.55B
• 1 day: -0.88%
• 5 days: -5.80%
• 1 month: -8.32%
• 3 months: -20.49%
• 6 months: -2.36%
• Year to date: -12.50%
• 1 year: -5.12%
• 5 years: -21.25%
• 10 years: -21.25%
• Sector: Healthcare
• Industry: Ophthalmic Goods

About: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Employees: 13,300

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

24% more call options, than puts

Call options by funds: $5.9M | Put options by funds: $4.75M

16% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 25

0% more funds holding

Funds holding: 110 [Q3] → 110 (+0) [Q4]

6% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 33

1.04% less ownership

Funds ownership: 10.74% [Q3] → 9.7% (-1.04%) [Q4]

15% less capital invested

Capital invested by funds: $729M [Q3] → $617M (-$112M) [Q4]

71% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 2 (-5) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 8% upside
• Avg. target: $19.71 25% upside
• High target: $24 52% upside

7 analyst ratings

• positive: 3 43%
• neutral: 3 43%
• negative: 1 14%

HC Wainwright & Co. Yi Chen 42% 1-year accuracy 67 / 161 met price target	27% upside $20	Buy Maintained	21 Feb 2025
RBC Capital Douglas Miehm 68% 1-year accuracy 15 / 22 met price target	14% upside $18	Outperform Maintained	20 Feb 2025
B of A Securities Craig Bijou 50% 1-year accuracy 4 / 8 met price target	8% upside $17	Underperform Maintained	20 Feb 2025
Stifel Thomas Stephan 44% 1-year accuracy 8 / 18 met price target	14% upside $18	Hold Maintained	29 Jan 2025
Wells Fargo Larry Biegelsen 66% 1-year accuracy 31 / 47 met price target	52% upside $24	Overweight Maintained	16 Jan 2025